BioCryst Pharmaceuticals Inc (BCRX) - Total Assets
Based on the latest financial reports, BioCryst Pharmaceuticals Inc (BCRX) holds total assets worth $465.05 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check BioCryst Pharmaceuticals Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
BioCryst Pharmaceuticals Inc - Total Assets Trend (1994–2025)
This chart illustrates how BioCryst Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of BioCryst Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.
BioCryst Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
BioCryst Pharmaceuticals Inc's total assets of $465.05 Million consist of 78.6% current assets and 21.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.5% |
| Accounts Receivable | $106.82 Million | 20.8% |
| Inventory | $5.40 Million | 1.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1994–2025)
This chart illustrates how BioCryst Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BCRX stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioCryst Pharmaceuticals Inc's current assets represent 78.6% of total assets in 2025, a decrease from 86.7% in 1994.
- Cash Position: Cash and equivalents constituted 17.5% of total assets in 2025, down from 21.1% in 1994.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1994.
- Asset Diversification: The largest asset category is accounts receivable at 20.8% of total assets.
BioCryst Pharmaceuticals Inc Competitors by Total Assets
Key competitors of BioCryst Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
BioCryst Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.91 | 2.93 | 2.30 |
| Quick Ratio | 1.88 | 2.88 | 2.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $178.23 Million | $270.12 Million | $150.20 Million |
BioCryst Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between BioCryst Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 56.59 |
| Latest Market Cap to Assets Ratio | 4.24 |
| Asset Growth Rate (YoY) | 4.8% |
| Total Assets | $514.16 Million |
| Market Capitalization | $2.18 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values BioCryst Pharmaceuticals Inc's assets at a significant premium (4.24x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: BioCryst Pharmaceuticals Inc's assets grew by 4.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BioCryst Pharmaceuticals Inc (1994–2025)
The table below shows the annual total assets of BioCryst Pharmaceuticals Inc from 1994 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $514.16 Million | +4.84% |
| 2024-12-31 | $490.42 Million | -5.13% |
| 2023-12-31 | $516.96 Million | -6.01% |
| 2022-12-31 | $550.00 Million | -6.49% |
| 2021-12-31 | $588.15 Million | +75.72% |
| 2020-12-31 | $334.71 Million | +90.96% |
| 2019-12-31 | $175.28 Million | +19.37% |
| 2018-12-31 | $146.84 Million | -17.62% |
| 2017-12-31 | $178.26 Million | +98.40% |
| 2016-12-31 | $89.85 Million | -27.87% |
| 2015-12-31 | $124.56 Million | -9.00% |
| 2014-12-31 | $136.87 Million | +180.10% |
| 2013-12-31 | $48.87 Million | -14.93% |
| 2012-12-31 | $57.44 Million | -30.13% |
| 2011-12-31 | $82.21 Million | -25.65% |
| 2010-12-31 | $110.57 Million | -22.24% |
| 2009-12-31 | $142.19 Million | +67.89% |
| 2008-12-31 | $84.69 Million | -40.66% |
| 2007-12-31 | $142.72 Million | +108.39% |
| 2006-12-31 | $68.49 Million | -31.00% |
| 2005-12-31 | $99.25 Million | +205.68% |
| 2004-12-31 | $32.47 Million | +7.88% |
| 2003-12-31 | $30.10 Million | -27.13% |
| 2002-12-31 | $41.30 Million | -30.11% |
| 2001-12-31 | $59.10 Million | -16.56% |
| 2000-12-31 | $70.83 Million | -3.51% |
| 1999-12-31 | $73.40 Million | +152.23% |
| 1998-12-31 | $29.10 Million | +9.81% |
| 1997-12-31 | $26.50 Million | -28.57% |
| 1996-12-31 | $37.10 Million | +183.21% |
| 1995-12-31 | $13.10 Million | +2.34% |
| 1994-12-31 | $12.80 Million | -- |
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more